A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant
We performed a prospective, randomized trial in CMV seronegative marrow recipients to determine if filtered blood products were as effective as CMV-seronegative blood products for the prevention of transfusion-transmitted CMV infection after marrow transplant. Before transplant, 502 patients were ra...
Gespeichert in:
| Veröffentlicht in: | Blood 1995-11, Vol.86 (9), p.3598-3603, Article 3598 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3603 |
|---|---|
| container_issue | 9 |
| container_start_page | 3598 |
| container_title | Blood |
| container_volume | 86 |
| creator | Bowden, Raleigh A. Slichter, Sherrill J. Sayers, Merlin Weisdorf, Daniel Cays, Monica Schoch, Gary Banaji, Meera Haake, Robert Welk, Kevin Fisher, Lloyd McCullough, Jeffrey Miller, Wesley |
| description | We performed a prospective, randomized trial in CMV seronegative marrow recipients to determine if filtered blood products were as effective as CMV-seronegative blood products for the prevention of transfusion-transmitted CMV infection after marrow transplant. Before transplant, 502 patients were randomized to receive either filtered or seronegative blood products. Patients were monitored for the development of CMV infection and tissue-documented CMV disease between days 21 and 100 after transplant. Infections occurring after day 21 from transplant were considered related to the transfusion of study blood products and, thus, were considered evaluable infections for the purpose of this trial. In the primary analysis of evaluable infections, there were no significant differences between the probability of CMV infection (1.3% v2.4%, P = 1.00) or disease (0% v 2.4%, P = 1.00) between the seronegative and filtered arms, respectively, or probability of survival (P - .6). In a secondary analysis of all infections occurring from day 0 to 100 post-transplant, although the infection rates were similar, the probability of CMV disease in the filtered arm was greater (2.4% v 0% in the seronegative arm, P = .03). However, the disease rate was still within the prestudy clinically defined acceptable rate of ≤5%. We conclude that filtration is an effective alternative to the use of seronegative blood products for prevention of transfusion-associated CMV infection in marrow transplant patients. |
| doi_str_mv | 10.1182/blood.V86.9.3598.bloodjournal8693598 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77568667</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120662796</els_id><sourcerecordid>77568667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-77535d92ba507c70ab6202160eb79ca7ecc831c850a29d0a997f98dd20f9b90f3</originalsourceid><addsrcrecordid>eNqVUsFu1DAUjBCoLIVPQPIBIZBIcJyNHR-XQKFoCwhKr5bjPINLEi-2E7TfxQ_ibFY9VEiIk-V5782M3zhJXuQ4y_OKvGw6a9vsqqIZz4qSV9kBuLajG2RXUT5jd5JVXpIqxZjgu8kKY0zTNWf5_eSB99cY5-uClCfJCSsZX1O-Sn5vUG37nXTG2wFZjc5MF8BBi7Yw_rBqHyD9DO2oIiKHFtX7YHv4Jjs7GTd69Ky-uHqOvoCzQ0SDmQC9mm2hT87GqeCRtg6F7xABmGAIZpG5dHLwevTxmm68t8rIECUiGzofNKhD30ZHK-hCOmd_LRO7Tg7hYXJPy87Do-N5mnw9e3NZv0u3H9-e15ttqijhIWWsLMqWk0aWmCmGZUMJJjnF0DCuJAOlqiJXVYkl4S2WnDPNq7YlWPOGY12cJk8X3p2zP0fwQfTGK-iiB7CjF1GAVpSy2Ph6aVTOeu9Ai50zvXR7kWMxZycOUYmYneBizkn8JbtI8_ioNzY9tDckx7Bi_cmxLr2SnY4LUcbftBUMU0JmN-9vuVEmyHmhwUnT3fI0_cvTh4UM4qInA054ZWCI38G4mJJorfm_R_4BYMXiSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77568667</pqid></control><display><type>article</type><title>A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Bowden, Raleigh A. ; Slichter, Sherrill J. ; Sayers, Merlin ; Weisdorf, Daniel ; Cays, Monica ; Schoch, Gary ; Banaji, Meera ; Haake, Robert ; Welk, Kevin ; Fisher, Lloyd ; McCullough, Jeffrey ; Miller, Wesley</creator><creatorcontrib>Bowden, Raleigh A. ; Slichter, Sherrill J. ; Sayers, Merlin ; Weisdorf, Daniel ; Cays, Monica ; Schoch, Gary ; Banaji, Meera ; Haake, Robert ; Welk, Kevin ; Fisher, Lloyd ; McCullough, Jeffrey ; Miller, Wesley</creatorcontrib><description>We performed a prospective, randomized trial in CMV seronegative marrow recipients to determine if filtered blood products were as effective as CMV-seronegative blood products for the prevention of transfusion-transmitted CMV infection after marrow transplant. Before transplant, 502 patients were randomized to receive either filtered or seronegative blood products. Patients were monitored for the development of CMV infection and tissue-documented CMV disease between days 21 and 100 after transplant. Infections occurring after day 21 from transplant were considered related to the transfusion of study blood products and, thus, were considered evaluable infections for the purpose of this trial. In the primary analysis of evaluable infections, there were no significant differences between the probability of CMV infection (1.3% v2.4%, P = 1.00) or disease (0% v 2.4%, P = 1.00) between the seronegative and filtered arms, respectively, or probability of survival (P - .6). In a secondary analysis of all infections occurring from day 0 to 100 post-transplant, although the infection rates were similar, the probability of CMV disease in the filtered arm was greater (2.4% v 0% in the seronegative arm, P = .03). However, the disease rate was still within the prestudy clinically defined acceptable rate of ≤5%. We conclude that filtration is an effective alternative to the use of seronegative blood products for prevention of transfusion-associated CMV infection in marrow transplant patients.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V86.9.3598.bloodjournal8693598</identifier><identifier>PMID: 7579469</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Viral - blood ; Biological and medical sciences ; Blood Banks - standards ; Blood Transfusion - methods ; Bone Marrow Transplantation - mortality ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Child ; Child, Preschool ; Cytomegalovirus - immunology ; Cytomegalovirus - isolation & purification ; Cytomegalovirus Infections - epidemiology ; Cytomegalovirus Infections - prevention & control ; Cytomegalovirus Infections - transmission ; Female ; Filtration ; Humans ; Infant ; Leukocytes - virology ; Male ; Mass Screening - standards ; Medical sciences ; Middle Aged ; Prospective Studies ; Survival Analysis ; Transfusion Reaction ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Blood, 1995-11, Vol.86 (9), p.3598-3603, Article 3598</ispartof><rights>1995 American Society of Hematology</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-77535d92ba507c70ab6202160eb79ca7ecc831c850a29d0a997f98dd20f9b90f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3706227$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7579469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bowden, Raleigh A.</creatorcontrib><creatorcontrib>Slichter, Sherrill J.</creatorcontrib><creatorcontrib>Sayers, Merlin</creatorcontrib><creatorcontrib>Weisdorf, Daniel</creatorcontrib><creatorcontrib>Cays, Monica</creatorcontrib><creatorcontrib>Schoch, Gary</creatorcontrib><creatorcontrib>Banaji, Meera</creatorcontrib><creatorcontrib>Haake, Robert</creatorcontrib><creatorcontrib>Welk, Kevin</creatorcontrib><creatorcontrib>Fisher, Lloyd</creatorcontrib><creatorcontrib>McCullough, Jeffrey</creatorcontrib><creatorcontrib>Miller, Wesley</creatorcontrib><title>A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant</title><title>Blood</title><addtitle>Blood</addtitle><description>We performed a prospective, randomized trial in CMV seronegative marrow recipients to determine if filtered blood products were as effective as CMV-seronegative blood products for the prevention of transfusion-transmitted CMV infection after marrow transplant. Before transplant, 502 patients were randomized to receive either filtered or seronegative blood products. Patients were monitored for the development of CMV infection and tissue-documented CMV disease between days 21 and 100 after transplant. Infections occurring after day 21 from transplant were considered related to the transfusion of study blood products and, thus, were considered evaluable infections for the purpose of this trial. In the primary analysis of evaluable infections, there were no significant differences between the probability of CMV infection (1.3% v2.4%, P = 1.00) or disease (0% v 2.4%, P = 1.00) between the seronegative and filtered arms, respectively, or probability of survival (P - .6). In a secondary analysis of all infections occurring from day 0 to 100 post-transplant, although the infection rates were similar, the probability of CMV disease in the filtered arm was greater (2.4% v 0% in the seronegative arm, P = .03). However, the disease rate was still within the prestudy clinically defined acceptable rate of ≤5%. We conclude that filtration is an effective alternative to the use of seronegative blood products for prevention of transfusion-associated CMV infection in marrow transplant patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Viral - blood</subject><subject>Biological and medical sciences</subject><subject>Blood Banks - standards</subject><subject>Blood Transfusion - methods</subject><subject>Bone Marrow Transplantation - mortality</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cytomegalovirus - immunology</subject><subject>Cytomegalovirus - isolation & purification</subject><subject>Cytomegalovirus Infections - epidemiology</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Cytomegalovirus Infections - transmission</subject><subject>Female</subject><subject>Filtration</subject><subject>Humans</subject><subject>Infant</subject><subject>Leukocytes - virology</subject><subject>Male</subject><subject>Mass Screening - standards</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Survival Analysis</subject><subject>Transfusion Reaction</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVUsFu1DAUjBCoLIVPQPIBIZBIcJyNHR-XQKFoCwhKr5bjPINLEi-2E7TfxQ_ibFY9VEiIk-V5782M3zhJXuQ4y_OKvGw6a9vsqqIZz4qSV9kBuLajG2RXUT5jd5JVXpIqxZjgu8kKY0zTNWf5_eSB99cY5-uClCfJCSsZX1O-Sn5vUG37nXTG2wFZjc5MF8BBi7Yw_rBqHyD9DO2oIiKHFtX7YHv4Jjs7GTd69Ky-uHqOvoCzQ0SDmQC9mm2hT87GqeCRtg6F7xABmGAIZpG5dHLwevTxmm68t8rIECUiGzofNKhD30ZHK-hCOmd_LRO7Tg7hYXJPy87Do-N5mnw9e3NZv0u3H9-e15ttqijhIWWsLMqWk0aWmCmGZUMJJjnF0DCuJAOlqiJXVYkl4S2WnDPNq7YlWPOGY12cJk8X3p2zP0fwQfTGK-iiB7CjF1GAVpSy2Ph6aVTOeu9Ai50zvXR7kWMxZycOUYmYneBizkn8JbtI8_ioNzY9tDckx7Bi_cmxLr2SnY4LUcbftBUMU0JmN-9vuVEmyHmhwUnT3fI0_cvTh4UM4qInA054ZWCI38G4mJJorfm_R_4BYMXiSA</recordid><startdate>19951101</startdate><enddate>19951101</enddate><creator>Bowden, Raleigh A.</creator><creator>Slichter, Sherrill J.</creator><creator>Sayers, Merlin</creator><creator>Weisdorf, Daniel</creator><creator>Cays, Monica</creator><creator>Schoch, Gary</creator><creator>Banaji, Meera</creator><creator>Haake, Robert</creator><creator>Welk, Kevin</creator><creator>Fisher, Lloyd</creator><creator>McCullough, Jeffrey</creator><creator>Miller, Wesley</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951101</creationdate><title>A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant</title><author>Bowden, Raleigh A. ; Slichter, Sherrill J. ; Sayers, Merlin ; Weisdorf, Daniel ; Cays, Monica ; Schoch, Gary ; Banaji, Meera ; Haake, Robert ; Welk, Kevin ; Fisher, Lloyd ; McCullough, Jeffrey ; Miller, Wesley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-77535d92ba507c70ab6202160eb79ca7ecc831c850a29d0a997f98dd20f9b90f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Viral - blood</topic><topic>Biological and medical sciences</topic><topic>Blood Banks - standards</topic><topic>Blood Transfusion - methods</topic><topic>Bone Marrow Transplantation - mortality</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cytomegalovirus - immunology</topic><topic>Cytomegalovirus - isolation & purification</topic><topic>Cytomegalovirus Infections - epidemiology</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Cytomegalovirus Infections - transmission</topic><topic>Female</topic><topic>Filtration</topic><topic>Humans</topic><topic>Infant</topic><topic>Leukocytes - virology</topic><topic>Male</topic><topic>Mass Screening - standards</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Survival Analysis</topic><topic>Transfusion Reaction</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bowden, Raleigh A.</creatorcontrib><creatorcontrib>Slichter, Sherrill J.</creatorcontrib><creatorcontrib>Sayers, Merlin</creatorcontrib><creatorcontrib>Weisdorf, Daniel</creatorcontrib><creatorcontrib>Cays, Monica</creatorcontrib><creatorcontrib>Schoch, Gary</creatorcontrib><creatorcontrib>Banaji, Meera</creatorcontrib><creatorcontrib>Haake, Robert</creatorcontrib><creatorcontrib>Welk, Kevin</creatorcontrib><creatorcontrib>Fisher, Lloyd</creatorcontrib><creatorcontrib>McCullough, Jeffrey</creatorcontrib><creatorcontrib>Miller, Wesley</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bowden, Raleigh A.</au><au>Slichter, Sherrill J.</au><au>Sayers, Merlin</au><au>Weisdorf, Daniel</au><au>Cays, Monica</au><au>Schoch, Gary</au><au>Banaji, Meera</au><au>Haake, Robert</au><au>Welk, Kevin</au><au>Fisher, Lloyd</au><au>McCullough, Jeffrey</au><au>Miller, Wesley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1995-11-01</date><risdate>1995</risdate><volume>86</volume><issue>9</issue><spage>3598</spage><epage>3603</epage><pages>3598-3603</pages><artnum>3598</artnum><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>We performed a prospective, randomized trial in CMV seronegative marrow recipients to determine if filtered blood products were as effective as CMV-seronegative blood products for the prevention of transfusion-transmitted CMV infection after marrow transplant. Before transplant, 502 patients were randomized to receive either filtered or seronegative blood products. Patients were monitored for the development of CMV infection and tissue-documented CMV disease between days 21 and 100 after transplant. Infections occurring after day 21 from transplant were considered related to the transfusion of study blood products and, thus, were considered evaluable infections for the purpose of this trial. In the primary analysis of evaluable infections, there were no significant differences between the probability of CMV infection (1.3% v2.4%, P = 1.00) or disease (0% v 2.4%, P = 1.00) between the seronegative and filtered arms, respectively, or probability of survival (P - .6). In a secondary analysis of all infections occurring from day 0 to 100 post-transplant, although the infection rates were similar, the probability of CMV disease in the filtered arm was greater (2.4% v 0% in the seronegative arm, P = .03). However, the disease rate was still within the prestudy clinically defined acceptable rate of ≤5%. We conclude that filtration is an effective alternative to the use of seronegative blood products for prevention of transfusion-associated CMV infection in marrow transplant patients.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>7579469</pmid><doi>10.1182/blood.V86.9.3598.bloodjournal8693598</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 1995-11, Vol.86 (9), p.3598-3603, Article 3598 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77568667 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Viral - blood Biological and medical sciences Blood Banks - standards Blood Transfusion - methods Bone Marrow Transplantation - mortality Bone marrow, stem cells transplantation. Graft versus host reaction Child Child, Preschool Cytomegalovirus - immunology Cytomegalovirus - isolation & purification Cytomegalovirus Infections - epidemiology Cytomegalovirus Infections - prevention & control Cytomegalovirus Infections - transmission Female Filtration Humans Infant Leukocytes - virology Male Mass Screening - standards Medical sciences Middle Aged Prospective Studies Survival Analysis Transfusion Reaction Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T12%3A05%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comparison%20of%20Filtered%20Leukocyte-Reduced%20and%20Cytomegalovirus%20(CMV)%20Seronegative%20Blood%20Products%20for%20the%20Prevention%20of%20Transfusion-Associated%20CMV%20Infection%20After%20Marrow%20Transplant&rft.jtitle=Blood&rft.au=Bowden,%20Raleigh%20A.&rft.date=1995-11-01&rft.volume=86&rft.issue=9&rft.spage=3598&rft.epage=3603&rft.pages=3598-3603&rft.artnum=3598&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V86.9.3598.bloodjournal8693598&rft_dat=%3Cproquest_cross%3E77568667%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77568667&rft_id=info:pmid/7579469&rft_els_id=S0006497120662796&rfr_iscdi=true |